About US
Contact us
-
EMA accepts Mylan’s MAA for proposed biosimilar trastuzumab for reviewThe European Medicines Agency (EMA) has accepted for review Mylan's marketing authorisation application (MAA) for a proposed biosimilar Trastuzumab, MYL-1401O, to treat certain human epidermal growth2016/8/25
-
Study shows new drug combination slows lung cancer cell growthScientists at the Institute of Cancer Research, London, and the Institut Gustave Roussy in France have shown that a new drug combination slows cancer cell growth in a type of non-small-cell lung cance2016/8/24
-
Pfizer to acquire AstraZeneca's anti-infectives business for $1.5bnPfizer has agreed to acquire small molecule anti-infectives business from AstraZeneca in a deal valued at approximately $1.5bn. With this deal, Pfizer will gain commercialisation and development righ2016/8/24
-
India develops world’s first leprosy vaccineIndia has developed the world’s first leprosy vaccine, which is soon to be planned for trials within five districts of Bihar and Gujarat states. The latest move is part of the country's efforts to el2016/8/23
-
Pfizer close to aquiring Medivation for approximately $14bnDrug giant Pfizer is close to signing a $14bn agreement to acquire biotech firm Medivation. Pfizer has been seeking acqusitions as the sales of its older drugs have slowed down, reported Bloomberg.2016/8/23
-
Deals this week: Omeros Corporation, Cytocentrics, Recro PharmaBio-pharmaceutical companyOmeros Corporationhas announced pricing for a public offering of 3,478,260 shares of its common stock to be $11.5 per share. Omeros is expected to raise gross proceeds of $42016/8/22
-
M&As this week: Mallinckrodt, Scintilla Pharmaceuticals, Lonza GroupMallinckrodt plchas announced plans to acquire Stratatech Corporation, a regenerative medicine company that develops proprietary skin substitute products. The acquisition is expected to strengthen Ma2016/8/22
-
Pfizer's Lyrica success a boon for Northwestern University endowmentPfizer’s Lyrica leads drug sales for the company--but it’s also doing big things for another of the med’s developers. Royalties on the nerve pain and seizure med have powered the endowment at Northwe2016/8/19
-
Merck joins Pfizer, Sanofi in high-stakes hunt for MedivationMerck & Co. wants Medivation, too. Not content to let another Big Pharma snap up the cancer-focused biotech unchallenged, Merck has joined the fight for a prize valued at more than $10 billion. R2016/8/19
-
J&J braces for biosim attack after losing last-ditch Remicade patent fightJohnson & Johnson lost its court battle to shieldRemicade from encroaching biosimilar competition. A U.S. District Judge on Wednesdaystruck down a key patent on the drug, clearing the way for Cell2016/8/18